STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[6-K] InflaRx N.V. Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

FORM 6-K


REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of November 2025
 
Commission File Number: 001-38283
 
 
InflaRx N.V.
(Translation of registrant's name into English)
 
 
Winzerlaer Str. 2
07745 Jena, Germany
(Address of principal executive office)


Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐
 


EXPLANATORY NOTE
 
Exhibits 99.1 and 99.2 to this report on Form 6-K (the “Report”) shall be deemed to be incorporated by reference into (i) the registration statements on Form S-8 (File No. 333-221656 and 333-240185) and (ii) the registration statement on Form F-3 (File No. 333-273058) of InflaRx N.V. and to be a part thereof from the date on which this Report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
 

EXHIBIT INDEX
 
Exhibit No.
Description
   
99.1
InflaRx N.V. Unaudited Condensed Consolidated Financial Statements as of and for the Nine Months Ended September 30, 2025
99.2
InflaRx N.V. Management’s Discussion and Analysis of Financial Condition and Results of Operations


SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
INFLARX N.V.
       
Date: November 10, 2025
By:
/s/ Niels Riedemann
 
 
Name:
Niels Riedemann
 
 
Title:
Chief Executive Officer
 



Inflarx

NASDAQ:IFRX

IFRX Rankings

IFRX Latest News

IFRX Latest SEC Filings

IFRX Stock Data

107.04M
63.42M
6.38%
24.96%
0.67%
Biotechnology
Healthcare
Link
Germany
Jena